Effects of icodextrin peritoneal dialysis solution on the peritoneal membrane in the STZ-induced diabetic rat model with partial nephrectomy

Nephrology Dialysis Transplantation

Volumn 25, Issue 5, 2010, Pages 1479-1488

  Nakao, Ai ^a   Nakao, Kazushi ^a   Takatori, Yuji ^a   Kojo, Syoichirou ^a   Inoue, Junko ^a   Akagi, Shigeru ^a   Sugiyama, Hitoshi ^a   Wada, Jun ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Diabetes; Fibrosis; Icodextrin; Peritoneal dialysis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; DIANEAL; EXTRANEAL; GLUCOSE; ICODEXTRIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; HISTOLOGY; IN VIVO STUDY; KIDNEY FAILURE; LONG TERM EXPOSURE; MALE; NONHUMAN; PARTIAL NEPHRECTOMY; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROBLAST GROWTH FACTOR 2; FIBROSIS; GLUCANS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMODIALYSIS SOLUTIONS; IMMUNOHISTOCHEMISTRY; MALE; NEPHRECTOMY; PERITONEUM; RATS; RATS, WISTAR; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951695087     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp479     Document Type: Article

References (45)

1. Nakai S, Masakane I, Akiba T et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial 2007; 11: 411-441
2. US Renal Data System. 2007 Annual Data Report. Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2007
3. De Vriese AS, Flyvbjerg A, Mortier S et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 2003; 14: 2109-2118 (Pubitemid 36909919)
4. Nakayama M, Kawaguchi Y, Yamada K et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182-186 (Pubitemid 27064536)
5. Peers E, Gokal R. Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume. Artif Organs 1998; 22: 8-12 (Pubitemid 28068862)
6. Cooker LA, Choo CG, Luneburg P et al.Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial 1999; 15: 17-20
7. Posthuma N, ter Wee PM, Niessen H et al. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin. Perit Dial Int 2001; 21: 43-51
8. de Fijter CW, Verbrugh HA, Oe LP et al. Biocompatibility of a glucose-polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 21: 411-418 (Pubitemid 23132907)
9. Jorres A, Gahl GM, Topley N et al. In-vitro biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 1994; 9: 785-790 (Pubitemid 2111127)
10. Bajo MA, Selgas R, Castro MA et al. Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo. Perit Dial Int 2000; 20: 742-747 (Pubitemid 32186003)
11. Posthuma N, ter Wee P, Donker AJ et al. Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients. Perit Dial Int 1999; 19: 334-342 (Pubitemid 30011696)
12. Tanabe K, Maeshima Y, Ichinose K et al. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int 2007; 71: 227-238 (Pubitemid 46160923)
13. Fukuoka N, Sugiyama H, Inoue T et al. Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice. Am J Nephrol 2008; 28: 661-668 (Pubitemid 351832454)
14. Ha H, Cha MK, Choi HN et al. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int 2002; 22: 171-177 (Pubitemid 34546327)
15. Liberek T, Topley N, Mistry CD et al. Cell function and viability in glucose polymer peritoneal dialysis fluids. Perit Dial Int 1993; 13: 104-111 (Pubitemid 23141702)
16. Plum J, Lordnejad MR, Grabensee B. Effect of alternative peritoneal dialysis solutions on cell viability, apoptosis/necrosis and cytokine expression in human monocytes. Kidney Int 1998; 54: 224-235 (Pubitemid 28288039)
17. Parikova A, Zweers MM, Struijk DG et al. Peritoneal effluent markers of inflammation in patients treated with icodextrin-based and glucose-based dialysis solutions. Adv Perit Dial 2003; 19: 186-190
18. Gotloib L, Wajsbrot V, Shostak A. Mesothelial dysplastic changes and lipid peroxidation induced by 7.5% icodextrin. Nephron 2002; 92: 142-155 (Pubitemid 34983888)
19. Aroeira LS, Aguilera A, Sanchez-Tomero JA et al. Epithelial to mes-enchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007; 18: 2004-2013 (Pubitemid 47041064)
20. Inagi R, Miyata T, Yamamoto T et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463: 260-264 (Pubitemid 30001930)
21. Barre DE, Chen C, Cooker L et al. Decreased in vitro formation of AGEs with extraneal solution compared to dextrose-containing peritoneal dialysis solutions. Adv Perit Dial 1999; 15: 12-16
22. Dawnay AB, Millar DJ. Glycation and advanced glycation end-product formation with icodextrin and dextrose. Perit Dial Int 1997; 17: 52-58 (Pubitemid 27475048)
23. Tomo T, Shibata T, Nasu M. Maillard reaction and AGE formation in glucose and polyglucose dialysis solutions. Perit Dial Int 1999; 19: 274-277 (Pubitemid 30015554)
24. Welten AG, Schalkwijk CG, ter Wee PM et al. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Perit Dial Int 2003; 23: 213-221
25. Yan SF, Ramasamy R, Naka Y et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169 (Pubitemid 37543056)
26. De Vriese AS, Tilton RG, Mortier S et al. Myofibroblast transdiffer-entiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21: 2549-2555 (Pubitemid 44644530)
27. Schwenger V, Morath C, Salava A et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199-207
28. Lu M, Kuroki M, Amano S et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101: 1219-1224 (Pubitemid 28145237)
29. Lee JH, Reddy DK, Saran R et al.Peritoneal accumulationofadvanced glycosylation end-products in diabetic rats on dialysis with icodextrin. Perit Dial Int 2000; 20(Suppl 5): S39-S47
30. Dobbie JW, Lloyd JK, Gall CA. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients. Adv Perit Dial 1990; 6: 3-12
31. Honda K, Nitta K, Horita S et al. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 1996; 72: 171-176 (Pubitemid 26035372)
32. Kang DH, Hong YS, Lim HJ et al. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimula-tion. Perit Dial Int 1999; 19: 221-230
33. Kumano K, Schiller B, Hjelle JT et al. Effects of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. Blood Purif 1996; 14: 165-169 (Pubitemid 26079583)
34. Ogata S, Yorioka N, Kohno N. Glucose and prednisolone alter basic fibroblast growth factor expression in peritoneal mesothelial cells and fibroblasts. J Am Soc Nephrol 2001; 12: 2787-2796 (Pubitemid 33115427)
35. De Vriese AS, Tilton RG, Stephan CC et al. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 2001; 12: 1734-1741
36. Honda K, Nitta K, Horita S et al. Accumulation of advanced glyca-tion end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14: 1541-1549 (Pubitemid 29241752)
37. Miyata T, Horie K, Ueda Y et al. Advanced glycation and lipidox-idation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58: 425-435 (Pubitemid 30429891)
38. Wang T, Cheng HH, Heimburger O et al. Effect of peritonitis on peritoneal transport characteristics: glucose solution versus polyglucose solution. Kidney Int 2000; 57: 1704-1712 (Pubitemid 30207929)
39. Combet S, Ferrier ML, Van Landschoot M et al. Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modificationsinthe peritoneum. J Am Soc Nephrol 2001; 12: 2146-2157 (Pubitemid 32880352)
40. Stoenoiu MS, De Vriese AS, Brouet A et al. Experimental diabetes induces functional and structural changes in the peritoneum. Kidney Int 2002; 62: 668-678 (Pubitemid 34779781)
41. Breborowicz A, Rodela H, Oreopoulos DG. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992; 41: 1280-1285
42. Ito T, Yorioka N, Yamamoto M et al. Effect of glucose on intercellular junctions of cultured human peritoneal mesothelial cells. J Am Soc Nephrol 2000; 11: 1969-1979
43. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66: 1257-1265 (Pubitemid 39121036)
44. Mortier S, Faict D, Lameire NH et al. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 2005; 67: 1559-1565 (Pubitemid 40463136)
45. Garcia-Lopez E, Pawlaczyk K, Anderstam B et al. Icodextrin metabolism and alpha-amylase activity in nonuremic rats undergoing chronic peritoneal dialysis. Perit Dial Int 2007; 27: 415-423 (Pubitemid 47202194)